GlobeNewswire Inc | Jun 28, 2021 01:00AM EDT

June 28, 2021

Dupixent (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis

-- Dupixent is the first and only available systemic treatment for atopic dermatitis that has been studied in adults for up to 3 years in a Phase 3 trial

PARIS and TARRYTOWN, N.Y. June 28, 2021- Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agencys Committee for Medicinal Products for Human Use.

Data from a single-arm Phase 3 open label extension (OLE) trial showed the long-term safety profile in adults with moderate-to-severe atopic dermatitis treated with Dupixent and observed up to three years was generally consistent with what was observed in the controlled pivotal Phase 3 trials. The OLE trial assessed the long-term safety of Dupixent 300 mg weekly in adults who had previously participated in Dupixent trials or had been screened for a Phase 3 trial. The approved Dupixent dose in adults is 300 mg every other week.

Atopic dermatitis is a chronic inflammatory disease of the skin that can be debilitating. Moderate-to-severe atopic dermatitis is characterized by intense persistent itch and skin lesions that can cover much of the body, resulting in skin dryness, cracking, redness or darkening, crusting and oozing. Itch is one of the most burdensome symptoms for patients. Moderate-to-severe atopic dermatitis can also have a substantial emotional and psychosocial impact on patients and their families, causing sleep disturbance, anxiety, depression and feelings of isolation.

Dupixent is the only biologic approved in the EU for children as young as six with severe atopic dermatitis and for adolescents and adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis (EoE). Dupixent is not an immunosuppressant and does not require ongoing lab monitoring. Dupixent is currently approved in more than 60 countries, and more than 260,000 patients have been treated globally.

About Dupixent Dupixent is approved in the EU for children (6-11 years) with severe atopic dermatitis, as well as for adolescents and adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy; for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment; and for adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Dupilumab Development ProgramTo date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation.

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3), allergic bronchopulmonary aspergillosis (Phase 3) and peanut allergy (Phase 2). These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietaryVelociSuitetechnologies, such asVelocImmune,which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi Investor Relations ? Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Nathalie Pham

Sanofi Media Relations ContactSally Bain Sanofi Investor Relations ? Contacts NorthTel.: +1 (781) 264-1091 AmericaSally.Bain@sanofi.com Felix Lauscher Fara Berkowitz Suzanne Greco



Sanofi IR main line: Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com https://www.sanofi.com/en/investors/contact



Regeneron Media Relations Contact Regeneron Investor Relations ContactHannah Kwagh Mark HudsonTel: +1 (914) 847-6314 Tel: +1 (914) 847-3482hannah.kwagh@regeneron.com Mark.Hudson@regeneron.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2020. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events orresults may differ materially from these forward-looking statements. Words suchas "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate,"variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron's business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron's and its collaborators' ability to continue to conduct research andclinical programs, Regeneron's ability to manage its supply chain, net productsales of products marketed or otherwise commercialized by Regeneron and/or itscollaborators (collectively, "Regeneron's Products"), and the global economy;the nature, timing, and possible success and therapeutic applications ofRegeneron's Products and product candidates being developed by Regeneron and/orits collaborators (collectively, ?Regeneron?s Product Candidates?) and researchand clinical programs now underway or planned, including without limitationDupixent^ (dupilumab) for the treatment of adults with moderate-to-severeatopic dermatitis; the likelihood, timing, and scope of possible regulatoryapproval and commercial launch of Regeneron's Product Candidates and newindications for Regeneron's Products, such as Dupixent for the treatment ofpediatric asthma, chronic obstructive pulmonary disease with evidence of type 2inflammation, pediatric atopic dermatitis, eosinophilic esophagitis, bullouspemphigoid, prurigo nodularis, chronic spontaneous urticaria, chronic inducibleurticaria-cold, chronic rhinosinusitis without nasal polyposis, allergic fungalrhinosinusitis, allergic bronchopulmonary aspergillosis, peanut allergy, andother potential indications; uncertainty of the utilization, market acceptance,and commercial success of Regeneron's Products and Regeneron?s ProductCandidates and the impact of studies (whether conducted by Regeneron or othersand whether mandated or voluntary), including the study discussed in this pressrelease, on any of the foregoing or any potential regulatory approval ofRegeneron's Products and Regeneron?s Product Candidates; the ability ofRegeneron's collaborators, suppliers, or other third parties (as applicable) toperform manufacturing, filling, finishing, packaging, labeling, distribution,and other steps related to Regeneron's Products and Regeneron?s ProductCandidates; the ability of Regeneron to manage supply chains for multipleproducts and product candidates; safety issues resulting from theadministration of Regeneron's Products (such as Dupixent) and Regeneron?sProduct Candidates in patients, including serious complications or side effectsin connection with the use of Regeneron's Products and Regeneron?s ProductCandidates in clinical trials; determinations by regulatory and administrativegovernmental authorities which may delay or restrict Regeneron's ability tocontinue to develop or commercialize Regeneron's Products and Regeneron?sProduct Candidates, including without limitation Dupixent; ongoing regulatoryobligations and oversight impacting Regeneron's Products, research and clinicalprograms, and business, including those relating to patient privacy; theavailability and extent of reimbursement of Regeneron's Products fromthird-party payers, including private payer healthcare and insurance programs,health maintenance organizations, pharmacy benefit management companies, andgovernment programs such as Medicare and Medicaid; coverage and reimbursementdeterminations by such payers and new policies and procedures adopted by suchpayers; competing drugs and product candidates that may be superior to, or morecost effective than, Regeneron's Products and Regeneron?s Product Candidates;the extent to which the results from the research and development programsconducted by Regeneron and/or its collaborators may be replicated in otherstudies and/or lead to advancement of product candidates to clinical trials,therapeutic applications, or regulatory approval; unanticipated expenses; thecosts of developing, producing, and selling products; the ability of Regeneronto meet any of its financial projections or guidance and changes to theassumptions underlying those projections or guidance; the potential for anylicense, collaboration, or supply agreement, including Regeneron's agreementswith Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or theirrespective affiliated companies, as applicable), to be cancelled or terminated;and risks associated with intellectual property of other parties and pending orfuture litigation relating thereto (including without limitation the patentlitigation and other related proceedings relating to EYLEA^ (aflibercept)Injection, Dupixent, Praluent^ (alirocumab), and REGEN-COV^TM (casirivimab andimdevimab)), other litigation and other proceedings and governmentinvestigations relating to the Company and/or its operations, the ultimateoutcome of any such proceedings and investigations, and the impact any of theforegoing may have on Regeneron's business, prospects, operating results, andfinancial condition. A more complete description of these and other materialrisks can be found in Regeneron's filings with the U.S. Securities and ExchangeCommission, including its Form 10-K for the year ended December 31, 2020 andits Form 10-Q for the quarterly period ended March 31, 2021. Anyforward-looking statements are made based on management's current beliefs andjudgment, and the reader is cautioned not to rely on any forward-lookingstatements made by Regeneron. Regeneron does not undertake any obligation toupdate (publicly or otherwise) any forward-looking statement, including withoutlimitation any financial projection or guidance, whether as a result of newinformation, future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).

Attachment

-- PDF